<p>Three new ruthenium(II)-arene complexes of the general formula [{(η<sup>6</sup>-<i>p</i>-cymene)Ru(L)}<sub>2</sub>](Cl)<sub>2</sub>), where L are monastrol (<b>L</b><sup><b>1</b></sup>), ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-pyrimidine-5-carboxylate (<b>L</b><sup><b>2</b></sup>) or its 4-bromophenyl analog (<b>L</b><sup><b>3</b></sup>), have been synthesized and characterized by elemental analysis, <sup>1</sup>H, <sup>13</sup>C, and 2-D NMR spectroscopy. The X-ray diffraction study of complex <b>1</b> showed the presence of a dicationic diruthenium complex where two thioxopyrimidines act as tridentate <i>μ,κN:κ</i><sup><i>2</i></sup><i>S</i> ligand, bridging two Ru ions through the pyrimidine nitrogen and sulfur atoms. All new complexes were evaluated <i>in vitro</i> for their antiviral activity against the replication of HIV-1 and HIV-2 in MT-4 cells using MTT assay. Additionally, complexes <b>1</b>–<b>3</b> were screened for their inhibitory activity against the ATPase enzyme and the motor-protein Kinesin Eg5. Complex <b>1</b> was found to inhibit microtubule-stimulated ATPase activity of kinesin of IC<sub>50</sub> = 30 μM (monastrol, IC<sub>50</sub> = 10 μM).</p
